HARROW, INC. (HROW): M&A transaction — Harrow completes Melt acquisition for ~$4.3M cash; outlines MELT-300 NDA timeline

HARROW, INC.

Paid ~$4.3M cash at closing for remaining Melt equity; contingent milestone payments unchanged.
Acquires Melt pipeline: MELT-300 (Phase 3, SPA), MELT-210, MELT-400; expands into procedural sedation.
Next steps for MELT-300: PK studies, NDA submission H1 2027, potential approval H1 2028, launch H2 2028.
MELT-300 is a sublingual midazolam/ketamine formulation; could be first FDA-approved non-opioid non-IV sedation.
Integration of Melt into Harrow's operations; leveraging MKO Melt network for commercial readiness.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

HARROW, INC. completed an acquisition involving Melt Pharmaceuticals, Inc. for approximately $4.3 million in cash (closed 2025-11-17).

Action: acquisition
Counterparty: Melt Pharmaceuticals, Inc.
Consideration: approximately $4.3 million in cash
Closing: 2025-11-17

Exact text from the filing

in the Company’s Current Report on Form 8-K filed on September 26, 2025, which description is incorporated herein by reference. At closing, the Company paid approximately $4.3 million in cash as initial consideration for the remaining equity interests of Melt. The contingent regulatory and commercial milestone payments described in the Company’s September 26,

View on SEC.gov

Browse all m&a transactions →

HARROW, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-023988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.